Precision diagnostics in transplanted organs using microarray-assessed gene expression: concepts and technical methods of the Molecular Microscope® Diagnostic System (MMDx)
Open Access
- 31 May 2024
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 138 (11) , 663-685
Abstract
There is a major unmet need for improved accuracy and precision in the assessment of transplant rejection and tissue injury. Diagnoses relying on histologic and visual assessments demonstrate significant variation between expert observers (as represented by low kappa values) and have limited ability to assess many biological processes that produce little histologic changes, for example, acute injury. Consensus rules and guidelines for histologic diagnosis are useful but may have errors. Risks of over- or under-treatment can be serious: many therapies for transplant rejection or primary diseases are expensive and carry risk for significant adverse effects. Improved diagnostic methods could alleviate healthcare costs by reducing treatment errors, increase treatment efficacy, and serve as useful endpoints for clinical trials of new agents that can improve outcomes. Molecular diagnostic assessments using microarrays combined with machine learning algorithms for interpretation have shown promise for increasing diagnostic precision via probabilistic assessments, recalibrating standard of care diagnostic methods, clarifying ambiguous cases, and identifying potentially missed cases of rejection. This review describes the development and application of the Molecular Microscope® Diagnostic System (MMDx), and discusses the history and reasoning behind many common methods, statistical practices, and computational decisions employed to ensure that MMDx scores are as accurate and precise as possible. MMDx provides insights on disease processes and highly reproducible results from a comparatively small amount of tissue and constitutes a general approach that is useful in many areas of medicine, including kidney, heart, lung, and liver transplants, with the possibility of extrapolating lessons for understanding native organ disease states.Keywords
Funding Information
- This research has been principally supported by grants from Genome Canada, Canada Foundation for Innovation, the University of Alberta Hospital Foundation, the Alberta Ministry of Advanced Education
- the Mendez National Institute of Transplantation Foundation, and Industrial Research Assistance Program. Partial support was also provided by funding from a licensing agreement with the One Lambda
- division of Thermo Fisher. Dr. Halloran held a Canada Research Chair in Transplant Immunology until 2008 and currently holds the Muttart Chair in Clinical Immunology.
This publication has 92 references indexed in Scilit:
- Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survivalAmerican Journal of Transplantation, 2024
- Optimization of gene expression microarray protocol for formalin-fixed paraffin-embedded tissuesGenomics Data, 2016
- Decision Tree and Ensemble Learning Algorithms with Their Applications in Bioinformatics2011
- Conceptual complexity and the bias/variance tradeoffCognition, 2011
- RNA expression analysis from formalin fixed paraffin embedded tissuesHistochemistry and Cell Biology, 2008
- Nodular Endocardial Infiltrates (Quilty Lesions) Cause Significant Variability in Diagnosis of ISHLT Grade 2 and 3A Rejection in Cardiac Allograft RecipientsThe Journal of Heart and Lung Transplantation, 2005
- Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation†Liver Transplantation, 2004
- Ensemble Methods in Machine Learning2000
- Is hepatic histology the true gold standard in diagnosing acute hepatic allograft rejection?Liver Transplantation and Surgery, 1996
- Acute cellular rejection after liver transplantation: Variability, morbidity, and mortalityLiver Transplantation and Surgery, 1995